Steadfast Toll Like Receptor 4 (
5-hydroxymethylcytosine
biomarkers
cell-free DNA
colon cancer
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
received:
16
07
2023
revised:
12
08
2023
accepted:
16
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Cell-free DNA (cfDNA) from patient blood is emerging as a noninvasive diagnostic avenue for various cancers. We aimed to identify reliable biomarkers in cfDNA by investigating genes exhibiting significant differences between colorectal cancer and control samples. Our objective was to identify genes that showed a positive difference between cancer and control samples. To achieve this, we conducted an in silico analysis to identify genes that exhibit no significant variation in methylation between genomic DNA (gDNA) and cfDNA. We collected experimental data from publicly available repositories, which included 5-hydroxymethylcytosine (5hmC) profiles of gDNA and cfDNA samples from both cancer patients and healthy individuals. By comparing and overlapping these two groups, we identified 187 genes of interest, of which 53 genes had a positive difference among colon cancer patients and healthy individuals. Next, we performed an ANOVA test on these genes, resulting in the identification of 12 genes that showed statistically significant higher levels of 5hmC in cfDNA and gDNA from cancer patients compared to healthy individuals. Additionally, we compared the 5hmC status of these genes between cfDNA and gDNA from cancer patients. Interestingly, we found that the 5hmC of the toll like receptor 4 (
Identifiants
pubmed: 37628686
pii: genes14081636
doi: 10.3390/genes14081636
pmc: PMC10454843
pii:
doi:
Substances chimiques
Toll-Like Receptor 4
0
5-hydroxymethylcytosine
1123-95-1
Cell-Free Nucleic Acids
0
TLR4 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Eur J Cancer Prev. 2017 Jan;26(1):17-26
pubmed: 27167150
Ann Oncol. 2020 Jun;31(6):745-759
pubmed: 33506766
PLoS One. 2017 Jan 26;12(1):e0170779
pubmed: 28125731
Pharmacogn Mag. 2016 May;12(Suppl 2):S237-44
pubmed: 27279714
Urol Oncol. 2015 Mar;33(3):110.e19-27
pubmed: 25499923
Cell Res. 2017 Oct;27(10):1243-1257
pubmed: 28925386
Gut. 2023 Feb;72(2):338-344
pubmed: 36604116
J Biol Chem. 1997 Aug 1;272(31):19575-81
pubmed: 9235963
Front Cell Dev Biol. 2021 Jun 01;9:651560
pubmed: 34141706
J Mol Biol. 2005 Nov 4;353(4):763-71
pubmed: 16213525
N Engl J Med. 2009 Sep 17;361(12):1179-87
pubmed: 19759380
Genome Res. 2012 Mar;22(3):467-77
pubmed: 22106369
Sci Rep. 2017 Mar 23;7:44990
pubmed: 28332554
J Cell Physiol. 2019 Dec;234(12):21707-21715
pubmed: 31144310
J Biol Chem. 1996 Oct 25;271(43):26706-12
pubmed: 8900148
Nat Commun. 2021 Apr 21;12(1):2357
pubmed: 33883548
Immunobiology. 2017 Jan;222(1):89-100
pubmed: 27349597
Mol Oncol. 2021 Jan;15(1):138-150
pubmed: 33107199
Cell Res. 2017 Oct;27(10):1231-1242
pubmed: 28820176
J Biol Chem. 1999 Aug 13;274(33):22941-8
pubmed: 10438459
Nat Chem. 2014 Dec;6(12):1049-55
pubmed: 25411882
Epigenetics. 2014 Jun;9(6):918-27
pubmed: 24694733
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809